Last Patient Enrolled in Pivotal Phase 3 Parkinson’s Disease Trial, Cynapsus Therapeutics Says
Cynapsus Therapeutics has enrolled the final patient in its pivotal Phase 3 clinical study investigating the clinical effects of APL-130277, a fast-acting sublingual thin film for the treatment of debilitating OFF states in Parkinson’s disease (PD). Dose-titration phase results and a final evaluation of the study are expected to be released by the…
